InvestSMART

Island Pharmaceuticals Limited (ASX: ILA) - Announcements

- Current share price for ILA : $0.405

ASX company news and announcements for Island Pharmaceuticals Limited (ILA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Island Pharmaceuticals Limited (ILA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Island Pharmaceuticals Limited (ILA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Island Pharmaceuticals Limited (ILA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$120 Investor Presentation - TechKnow Invest Roadshow 27 Jul 2026 9:23AM $0.400 $0.405 risen by 1.25%
$120 Notification regarding unquoted securities - ILA 13 Jul 2026 4:29PM $0.480 $0.405 fallen by 15.63%
$120 Notification regarding unquoted securities - ILA 13 Jul 2026 4:27PM $0.480 $0.405 fallen by 15.63%
$120 Notification regarding unquoted securities - ILA 13 Jul 2026 4:21PM $0.480 $0.405 fallen by 15.63%
$120 Notification regarding unquoted securities - ILA 13 Jul 2026 4:21PM $0.480 $0.405 fallen by 15.63%
$120 Texas Biomed SOW accelerates pivotal FDA pathway 13 Jul 2026 9:46AM $0.450 $0.405 fallen by 10%
$120 Investor Presentation - Ebola Clinical Program 8 Jul 2026 10:02AM $0.480 $0.405 fallen by 15.63%
$120 Notification of cessation of securities - ILA 8 Jul 2026 9:00AM $0.475 $0.405 fallen by 14.74%
$120 Galidesivir approved for treatment use in in Ebola epidemic 7 Jul 2026 9:02AM $0.375 $0.405 risen by 8%
$120 Trading Halt 3 Jul 2026 12:23PM $0.375 $0.405 risen by 8%
$120 Pause in Trading 3 Jul 2026 12:01PM $0.375 $0.405 risen by 8%
$120 Singapore Patent Expands Island's ISLA 101 Viral Protection 2 Jul 2026 9:38AM $0.375 $0.405 risen by 8%
$120 FDA Grants Orphan Designation for Galidesivir in Marburg 17 Jun 2026 8:54AM $0.355 $0.405 risen by 14.08%
$120 Investor Presentation - Asia Dengue Summit 16 Jun 2026 9:58AM $0.365 $0.405 risen by 10.96%
$120 Investor presentation (updated) 11 Jun 2026 12:25PM $0.365 $0.405 risen by 10.96%
$120 Investor presentation 11 Jun 2026 9:46AM $0.365 $0.405 risen by 10.96%
$120 Island Secures USAMRIID Support for Galidesivir Study 10 Jun 2026 8:53AM $0.350 $0.405 risen by 15.71%
$120 Island Advances Galidesivir GMP Manufacturing for Biodefence 4 Jun 2026 9:03AM $0.370 $0.405 risen by 9.46%
$120 Island Adds Biodefence Leader as Filovirus Risks Escalate 21 May 2026 9:25AM $0.400 $0.405 risen by 1.25%
$120 Island Bolsters US Biodefence Readiness Ahead of Trials 19 May 2026 8:44AM $0.425 $0.405 fallen by 4.71%
$120 Cleansing Notice 28 Apr 2026 8:30AM $0.380 $0.405 risen by 6.58%
$120 Application for quotation of securities - ILA 28 Apr 2026 8:23AM $0.380 $0.405 risen by 6.58%
$120 Quarterly Appendix 4C and Activities Report 27 Apr 2026 9:46AM $0.375 $0.405 risen by 8%
$120 Cleansing Notice 30 Mar 2026 11:19AM $0.370 $0.405 risen by 9.46%
$120 Application for quotation of securities - ILA 30 Mar 2026 11:17AM $0.370 $0.405 risen by 9.46%

1 - 25 of 442 results

Page 1 of 18

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.